{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:12:45Z","timestamp":1774627965372,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen High-level Hospital Construction Fund and Shenzhen Clinical Research Center for Tuberculosis","award":["20210617141509001"],"award-info":[{"award-number":["20210617141509001"]}]},{"name":"Shenzhen High-level Hospital Construction Fund","award":["XKJS-2025033"],"award-info":[{"award-number":["XKJS-2025033"]}]},{"name":"Shenzhen fund for Guangdong provincial high-level clinical key specialities","award":["SZGSP010"],"award-info":[{"award-number":["SZGSP010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13318-026-00985-4","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:56:50Z","timestamp":1769695010000},"page":"157-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Validated LC\u2013MS\/MS Method for Unbound Rifapentine Quantitation Reveals Nonlinear Plasma Protein Binding and Comparable Free Fractions Between Adults and Children with Tuberculosis"],"prefix":"10.1007","volume":"51","author":[{"given":"Wenmei","family":"Qiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaona","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"6","key":"985_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2165\/00003088-198611060-00003","volume":"11","author":"CK Svensson","year":"1986","unstructured":"Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet. 1986;11(6):450\u201369. https:\/\/doi.org\/10.2165\/00003088-198611060-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"985_CR2","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1128\/AAC.01730-13","volume":"58","author":"EF Egelund","year":"2014","unstructured":"Egelund EF, Weiner M, Singh RP, Prihoda TJ, Gelfond JA, Derendorf H, et\u00a0al. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2014;58(8):4904\u201310. https:\/\/doi.org\/10.1128\/AAC.01730-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"985_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17425255.2019.1648432","volume":"15","author":"C Sekaggya-Wiltshire","year":"2019","unstructured":"Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2019;15(8):615\u20138. https:\/\/doi.org\/10.1080\/17425255.2019.1648432.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"985_CR4","volume-title":"Module 5: Management of Tuberculosis in Children and Adolescents","author":"WHO Consolidated Guidelines on Tuberculosis","year":"2022","unstructured":"WHO Consolidated Guidelines on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents. Geneva: World Health Organization; 2022."},{"issue":"8","key":"985_CR5","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1128\/AAC.00031-16","volume":"60","author":"TJ Zurlinden","year":"2016","unstructured":"Zurlinden TJ, Eppers GJ, Reisfeld B. Physiologically based pharmacokinetic model of rifapentine and 25-desacetyl rifapentine disposition in humans. Antimicrob Agents Chemother. 2016;60(8):4860\u20138. https:\/\/doi.org\/10.1128\/AAC.00031-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"985_CR6","volume-title":"Global Tuberculosis Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023."},{"issue":"15","key":"985_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169\u201383. https:\/\/doi.org\/10.2165\/00003495-200262150-00001.","journal-title":"Drugs"},{"issue":"5","key":"985_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","volume":"40","author":"WJ Burman","year":"2001","unstructured":"Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327\u201341. https:\/\/doi.org\/10.2165\/00003088-200140050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"985_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","volume":"56","author":"B Jarvis","year":"1998","unstructured":"Jarvis B, Lamb HM. Rifapentine. Drugs. 1998;56(4):607\u201317. https:\/\/doi.org\/10.2165\/00003495-199856040-00008.","journal-title":"Drugs"},{"key":"985_CR10","first-page":"612","volume":"2","author":"DA Mitchison","year":"1998","unstructured":"Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis. 1998;2:612\u20135 (PMID: 9712273).","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"985_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","volume":"91","author":"KE Dooley","year":"2012","unstructured":"Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, et\u00a0al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):881\u20138. https:\/\/doi.org\/10.1038\/clpt.2011.323.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"985_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00007691-199302000-00005","volume":"15","author":"WM Cai","year":"1993","unstructured":"Cai WM, Zhu GZ, Chen G. Free phenytoin monitoring in serum and saliva of epileptic patients in China. Ther Drug Monit. 1993;15(1):31\u20134. https:\/\/doi.org\/10.1097\/00007691-199302000-00005.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"985_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00007691-200306000-00025","volume":"25","author":"R Mandla","year":"2003","unstructured":"Mandla R, Line PD, Midtvedt K, Bergan S. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit. 2003;25(3):407\u201314. https:\/\/doi.org\/10.1097\/00007691-200306000-00025.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"985_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/01.ftd.0000173373.12569.c7","volume":"27","author":"GA McMillin","year":"2005","unstructured":"McMillin GA, Juenke J, Dasgupta A. Effect of ultrafiltrate volume on determination of free phenytoin concentration. Ther Drug Monit. 2005;27(5):630\u20133. https:\/\/doi.org\/10.1097\/01.ftd.0000173373.12569.c7.","journal-title":"Ther Drug Monit"},{"key":"985_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.13699\/j.cnki.1001-6821.2008.03.016","volume":"03","author":"B Chen","year":"2008","unstructured":"Chen B, Cai W. Progress in monitoring of free drug concentration and its clinical application. Chin J Clin Pharmacol. 2008;03:255\u20139. https:\/\/doi.org\/10.13699\/j.cnki.1001-6821.2008.03.016.","journal-title":"Chin J Clin Pharmacol"},{"issue":"1","key":"985_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","volume":"24","author":"JS Kang","year":"2009","unstructured":"Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1\u201310. https:\/\/doi.org\/10.3904\/kjim.2009.24.1.1.","journal-title":"Korean J Intern Med"},{"issue":"11","key":"985_CR17","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.tibtech.2020.03.001","volume":"38","author":"HC Ates","year":"2020","unstructured":"Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C. On-site therapeutic drug monitoring. Trends Biotechnol. 2020;38(11):1262\u201377. https:\/\/doi.org\/10.1016\/j.tibtech.2020.03.001.","journal-title":"Trends Biotechnol"},{"issue":"2","key":"985_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jchromb.2004.07.032","volume":"810","author":"A Aresta","year":"2004","unstructured":"Aresta A, Palmisano F, Zambonin CG, Schena P, Grandaliano G. Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;810(2):197\u2013202. https:\/\/doi.org\/10.1016\/j.jchromb.2004.07.032.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"11","key":"985_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.13699\/j.cnki.1001-6821.2024.11.020","volume":"40","author":"T Ke","year":"2024","unstructured":"Ke T, He T, Zhang P-z, L W, Zhou Y, Wang F, et\u00a0al. Determination of rifapentine concentration in human serum by two-dimensional liquid chromatography. Chin J Clin Pharmacol. 2024;40(11):1638\u201341. https:\/\/doi.org\/10.13699\/j.cnki.1001-6821.2024.11.020.","journal-title":"Chin J Clin Pharmacol"},{"key":"985_CR20","unstructured":"FDA. Bioanalytical Method Validation Guidance [EB\/OL]. (2018-05-25) [2019-11-23]. https:\/\/www.fda.gov\/regulatory--information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry."},{"issue":"13","key":"985_CR21","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1021\/ac020361s","volume":"75","author":"BK Matuszewski","year":"2003","unstructured":"Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2013MS\/MS. Anal Chem. 2003;75(13):3019\u201330. https:\/\/doi.org\/10.1021\/ac020361s.","journal-title":"Anal Chem"},{"issue":"1-2","key":"985_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","volume":"377","author":"A Dasgupta","year":"2007","unstructured":"Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377(1\u20132):1\u201313. https:\/\/doi.org\/10.1016\/j.cca.2006.08.026.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"985_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.seizure.2007.12.007","volume":"17","author":"K Chan","year":"2008","unstructured":"Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure. 2008;17(6):572\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2007.12.007.","journal-title":"Seizure"},{"issue":"2","key":"985_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2146\/ajhp140191","volume":"72","author":"HG Gibbs","year":"2015","unstructured":"Gibbs HG, Zimmerman DE, Shermock KM, Clarke W, Mirski MA, Lewin JJ 3rd. Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients. Am J Health Syst Pharm. 2015;72(2):121\u20136. https:\/\/doi.org\/10.2146\/ajhp140191.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"985_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2125.1989.tb03548.x","volume":"28","author":"IA Choonara","year":"1989","unstructured":"Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. Br J Clin Pharmacol. 1989;28(5):599\u2013604. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03548.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"985_CR26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1124\/dmd.110.037192","volume":"39","author":"SJ Miyagi","year":"2011","unstructured":"Miyagi SJ, Collier AC. The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos. 2011;39(5):912\u20139. https:\/\/doi.org\/10.1124\/dmd.110.037192.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"985_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2551-x","volume":"36","author":"SA Smith","year":"2018","unstructured":"Smith SA, Waters NJ. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm Res. 2018;36(2):30. https:\/\/doi.org\/10.1007\/s11095-018-2551-x.","journal-title":"Pharm Res"},{"issue":"10","key":"985_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/glycob\/cwv041","volume":"25","author":"CL Fernandes","year":"2015","unstructured":"Fernandes CL, Ligabue-Braun R, Verli H. Structural glycobiology of human \u03b11-acid glycoprotein and its implications for pharmacokinetics and inflammation. Glycobiology. 2015;25(10):1125\u201333. https:\/\/doi.org\/10.1093\/glycob\/cwv041.","journal-title":"Glycobiology"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-00985-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:23:47Z","timestamp":1774625027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-00985-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-00985-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Shenzhen High-Level Hospital Construction Fund and Shenzhen Clinical Research Center for Tuberculosis (20210617141509001), Shenzhen High-level Hospital Construction Fund (XKJS-2025033), Shenzhen fund for Guangdong provincial high-level clinical key specialities (no. SZGSP010), Shenzhen Medical Research Fund from Shenzhen Medical Academy of Research and Translation (SMART) (no. C2405002), and Shenzhen Third People\u2019s Hospital (no. G2022058).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by the Research Ethics Committee of the Third People\u2019s Hospital of Shenzhen (ethics approval no. 2022-096-02).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all adult participants or legal guardians of pediatric participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent for publication was obtained from all participants or their legal guardians as part of the informed consent process.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Wenmei Qiao: Methodology, investigation, and writing \u2013 original draft. Mutong Fang: Formal analysis and data curation. Miaona Liu: Resources and validation. Tian He: Methodology and software. Peize Zhang: Conceptualization, supervision, and writing\u2014review and editing. Wei Li: Project administration, funding acquisition, supervision, and writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}